Extracorporeal Removal of Antimicrobials during Plasmapheresis

Journal of Clinical Apheresis

Volumn 18, Issue 4, 2003, Pages 194-205

  Kintzel, Polly E ^a,d   Eastlund, Ted ^b   Calis, Karim Anton ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NONE   (United States)

Author keywords

Antibiotics; Clearance; Dosages; Drugs; Medications; Pharmacokinetics; Plasma exchange

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

BINDING AFFINITY; CONFERENCE PAPER; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; HUMAN; PLASMAPHERESIS;

ACYCLOVIR; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEFTRIAXONE; CLINICAL TRIALS; HUMANS; PLASMA EXCHANGE; PLASMAPHERESIS; TOBRAMYCIN; VANCOMYCIN;

EID: 0346786557     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.10074     Document Type: Conference Paper

References (37)

1. Smith JW, Weinstein R, Hillyer K. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003;43:820-822.
2. Brecher ME. Plasma exchange: why we do what we do. J Clin Apheresis 2002;17:207-211.
3. Guillevin L. Synchronization of plasma exchange and adjuvant treatments. Transfusion Sci 1999;19:27-33.
4. Kale-Pradhan PB, Woo MH. A review of the effects of plasmapheresis on drug clearance. Pharmacotherapy 1997;17:684-695.
5. Hardman JG, Limbird LE, Goodman Gilman A, editors, Goodman and Gilman's: the pharmacologic basis of therapeutics, 10th ed. New York: McGraw-Hill. 2001. p 6-10, 1209-1212, 1219, 1262, 1315-1317, 1925, 1928, 1938, 1958, 1972 2014, 2019.
6. Fauvelle F, Petitjean O, Tod M, Guillevin L. Clinical pharmacokinetics during plasma exchange. Therapie 2000;55:269-275.
7. Benoni G, Arosio E, Raimondi MG, Pancera P, Lechi A, Velo GP. Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid. J Antimicrob Chemother 1985;16:267-273.
8. Integrated Information® Search. Micromedex. Available at URL: http://csi.micromedex.com/fraMain.asp? (Accessed June 25, 2003).
9. Fauvelle F, Lortholary O, Tod M, Guillevin L, Louchahi M, Leon A, Petitjean O. Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients. Antimicrob Agent Chemother 1994;38:1519-1522.
10. Bakken JS, Cavalieri SJ, Gangeness D, Kubat T, Pollack JR. Influence of therapeutic plasmapheresis on elimination of ceftriaxone. Antimicrob Agent Chemother 1993;37:1171-1173.
11. Drusano GL, Standiford HC, Fitzpatrick B, Leslie J, Tangtatsawasdi P, Ryan P, Tatem B, Moody MR, Schimpff C. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agent Chemother 1984;26:388-393.
12. Tjandramaga TB, van Hecken A, Mullie A, Verbesselt R, de Schepper PJ, Verbist L. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agent Chemother 1982;22:237-241.
13. Ljungberg B, Nilsson-Ehle I. Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males. Eur J Clin Pharmacol 1988;34:179-186.
14. Boeckh M, Lode H, Borner K, Höffken G, Wagner J, Koeppe P. Pharmacokinetics and serum bacteriocidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agent Chemother 1988;32:92-95.
15. Fortaz® (ceftazidime for injection), package insert. Glaxo-SmithKline, Research Triangle Park, NC: GlaxoSmithKline. April 2002.
16. Bozkurt F, Schollmeyer P, Keller E. Kinetics of ceftazidime during plasmapheresis. Eur J Clin Pharmacol 1987;33:197-201.
17. Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, Inc. 1992. p 15-1-15-31.
18. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuck RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agent Chemother 1982;22:391-394.
19. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agent Chemother 1982;21:575-580.
20. McClellan SD, Whitaker CH, Friedberg RC. Removal of vancomycin during plasmapheresis. Ann Pharmacother 1997;31:1132-1136.
21. Brophy DF, Mueller BA. Vancomycin removal by plasmapheresis. Ann Pharmacother 1996;30:1038 [Letter].
22. Osman BA, Lew SQ. Vancomycin removal by plasmapheresis. Pharmacol Toxicol 1997;81:245-246.
23. Foral PA, Heinman SM. Vancomycin removal during a plasma exchange transfusion. Ann Pharmacother 2001;35:1400-1402.
24. Péchère JC, Roy B, Dugal R. Distribution and elimination kinetics of intravenously and intramuscularly administered tobramycin in man. Int J Clin Pharmacol 1976;14:313-318.
25. Anderson PO, Knoben JE, Troutman WG, editors. Handbook of clinical drug data, 10th ed. McGraw-Hill. New York: 2001. p 57.
26. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, Inc. 1992. p 14-1-14-47.
27. Oullette SM, Visconti JA, Kennedy MS. A pharmacokinetic evaluation of the effect of plasma exchange on tobramycin disposition. Clin Exp Dialysis Apheresis 1983;7:225-233.
28. Kale-Pradhan PB, Dehoorne-Smith ML, Jaworski DA, Hare BL, Provenzano R, Higgins MJ. Evaluation of plasmapheresis on the removal of tobramycin. Pharmacotherapy 1995;15:673-676.
29. Applegate R, Schwartz D, Bennett WM. Removal of tobramycin during plasma exchange therapy. Ann Intern Med 1981;94:820-821 [Letter].
30. Moore RD, Leitman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 1987;155:93-99.
31. Blum MR, Liao SHT, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982;73:186-192.
32. Spector SA, Connor JD, Hintz M, Quinn RP, Blum MR, Keeney RE. Single-dose pharmacokinetics of acyclovir. Antimicrob Agent Chemother 1981;19:608-612.
33. de Miranda P, Good SS, Laskin OL, Krasny HC, Connor JD, Lietman PS. Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther 1981;30:662-672.
34. Zovirax® (acyclovir sodium) for injection, package insert, GlaxoSmithKline. Research Triangle Park, NC: GlaxoSmith-Kline, January 2001.
35. Chavanet PY, Bailly F, Mousson C, Waldner-Combernoux A, Lokiec F, Rebibou JM, Chalopin JM, Portier H. Acyclovir pharmacokinetics in plasmapheresis. J Clin Apheresis 1990;5:68-69.
36. Evans WE, Schentag JJ, Jusko WJ, Relling RV, editors. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Inc. Vancouver, WA: 1992. p 10-16.
37. Zosyn® (piperacillin and tazobactam injection), package insert, Lederle Piperacillin, Inc. Carolina, Puerto Rico: Lederle Piperacillin, Inc. April 2003.